WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Roche
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Webinar
Conference
Abbott | November 29, 2016
Biotechnology Reagents Market by Technology (Chromatography, Electrophoresis, PCR, Mass Spectrometry, Flow Cytometry, Expression & Transfection) for DNA & RNA Analysis, Protein Purification, Drug Testing, Gene Expression and by End user: Global Industry Perspective, Comprehensive Analysis, Size, Share, Growth, Segment, Trends and Forecast, 2015 – 2021.Global biotechnology reagents market is expected to reach USD 94.6 billion in 2021, growing at a CAGR of 9.0% during 2016 and 2021....
biopharmadive | July 10, 2017
In an unexpected move, Shire International has secured an injunction in a Hamburg, Germany court against Roche for the Swiss pharma's as yet unmarketed hemophilia drug, emicizumab. The injunction claims Roche is disseminating "inaccurate and misleading characterization of the serious adverse events that occurred in the HAVEN 1 Phase 3 trial of emicizumab, as well as misinformation about "the appropriate management of breakthrough bleeds uncontrolled by emicizumab....
fiercebiotech | July 05, 2017
Clementia Pharmaceuticals has filed to raise $115 million in an IPO. The Canadian biotech wants the cash to bankroll late-phase trials of an oral retinoic acid receptor gamma agonist it licensed from Roche. Montreal, Canada-based Clementia intends to use the IPO money to take the former Roche drug, palovarotene, through two phase 3 trials in fibrodysplasia ossificans progressiva (FOP). If the data are good, Clementia plans to file for approval and make palovarotene the go-to drug for the ...
Labiotech.eu | January 28, 2020
A Swiss research group has developed tiny plastic particles that could carry gene therapies to the center of the cell with less risk of getting attacked by the immune system than conventional gene therapies. The majority of gene therapies in use today are delivered to the DNA of target cells using viral vectors. While efficient at their job, viral vectors can risk triggering the immune system to destroy them. This can lead to the therapy becoming ineffective....
Video
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE